Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia

Blood Adv. 2019 Nov 12;3(21):3333-3336. doi: 10.1182/bloodadvances.2019000289.

Abstract

  1. This is the first report of successful treatment of therapy-resistant leptomeningeal T-PLL with intrathecal alemtuzumab.

  2. Intrathecal alemtuzumab is a potentially safe and efficacious therapeutic alternative for treatment of leptomeningeal T-PLL.

Publication types

  • Case Reports

MeSH terms

  • Alemtuzumab / administration & dosage*
  • Antineoplastic Agents, Immunological / administration & dosage*
  • Biopsy
  • Blood Cell Count
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Immunophenotyping
  • Injections, Spinal
  • Leukemia, Prolymphocytic, T-Cell / drug therapy*
  • Leukemia, Prolymphocytic, T-Cell / mortality
  • Leukemia, Prolymphocytic, T-Cell / pathology*
  • Meningeal Neoplasms / diagnosis
  • Meningeal Neoplasms / drug therapy*
  • Meningeal Neoplasms / mortality
  • Meningeal Neoplasms / secondary*
  • Middle Aged
  • Molecular Targeted Therapy / methods
  • Retreatment
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Alemtuzumab